Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.68 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CD38 | P28907 | 1/20 | 0.38 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23697846 | 0.87 | EGFR (0.68) | EGFRARIRAK4ABL1LMNA | |
| SCHEMBL25587995 | 0.84 | EGFR (0.60) | EGFRARIRAK4PIK3CDPIK3CA | |
| SCHEMBL17198305 | 0.83 | EGFR (0.63) | EGFRARIRAK4PIK3CDPIK3CA | |
| SCHEMBL4481815 | 0.81 | EGFR (1.00) | EGFRARPIK3CDPIK3CAFGFR4 | |
| SCHEMBL28041954 | 0.77 | EGFR (0.69) | EGFRARIRAK4PIK3CDPIK3CA | |
| SCHEMBL24783500 | 0.77 | EGFR (0.69) | EGFRARPIK3CDPIK3CAFGFR4 | |
| SCHEMBL24782968 | 0.77 | EGFR (0.68) | EGFRARIRAK4PIK3CDPIK3CA | |
| SCHEMBL12890449 | 0.77 | EGFR (0.42) | EGFRABL1SMN1; SMN2 | |
| SCHEMBL23055235 | 0.77 | EGFR (0.68) | EGFRARIRAK4PIK3CDPIK3CA | |
| SCHEMBL2998449 | 0.77 | EGFR (0.68) | EGFRARPIK3CDPIK3CAFGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242565-A1 | Macrolides with Modified Desosamine Sugars and Uses Thereof | ZIKANI THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| US-11673910-B2 | Macrolides with modified desosamine sugars and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2023-06-13 | — | — | US | disclosed |
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2023-04-13 | — | — | US | disclosed |
| WO-2021149767-A1 | HETEROCYCLIC DERIVATIVE | 大日本住友製薬株式会社 | 2021-07-29 | — | — | WO | disclosed |
| WO-2020017587-A1 | PYRIDAZINONE DERIVATIVE | 大日本住友製薬株式会社 | 2020-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673910-B2 | Macrolides with modified desosamine sugars and uses thereof | FUT6, DDOST, MGAM | EGFR 3594/4885AR 3770/4885IRAK4 926/4885 |
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | MAPT, PSEN1, PSEN2 | EGFR 4765/4885AR 3678/4885IRAK4 4342/4885 |
| US-20230242565-A1 | Macrolides with Modified Desosamine Sugars and Uses Thereof | FUT6, DDOST, MGAM | EGFR 3594/4885AR 3770/4885IRAK4 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.